Changes in Iron Markers Following Iron Loading in Hemodialysis Patients
NCT ID: NCT00308490
Last Updated: 2007-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
160 participants
INTERVENTIONAL
2005-09-30
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients
NCT02198495
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients
NCT00233597
Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients
NCT04134026
Effect of Two Iron Preparations on Protein in the Urine
NCT00354692
Intravenous Iron in Patients With Anemia of Chronic Kidney Disease
NCT00204256
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
iron sucrose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stable epoetin dose for two months minimum
* serum ferritin concentration \< 1000 ng/ml
* transferrin saturation \< 50%
* parathormone concentration \< 800 pg/ml
Exclusion Criteria
* serum ferritin concentration \< 20 ng/ml
* vitamin B12 and/or folic deficiency
* other hematologic disease than anemia
* cancer
* hypothyroidism
* infectious disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Papageorgiou General Hospital
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Efstathios Mitsopoulos, MD
Role: PRINCIPAL_INVESTIGATOR
Papageorgiou General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Papageorgiou General Hospital
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
48/31-1-2005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.